Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from ADMA Biologics

Top-Rated Stocks: ADMA Biologics Sees Composite Rating Climb To 96

ADMA Biologics saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96.

Investors Business Daily

Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits

ADMA stock plummeted Thursday after the biotech company slightly missed the Street's first-quarter expectations.

Investors Business Daily

3 Mid-Cap Medical Stocks Outperforming the Market

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump Tariffs Trigger Bear Market. Investor Focus Shifts Here.

A bear market takes hold as Trump tariffs hammer stocks. With IBD Leaderboard trimmed to just seven names, safety and preparation are in focus.

Investors Business Daily

How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback

ADMA Biologics is Thursday's IBD Stock Of The Day. After an accounting debacle hammered shares in 2024, ADMA stock is making a comeback.

Investors Business Daily

ADMA Stock Builds A Base As Profits Continue To Soar

This biopharmaceutical firm specializes in treatments to prevent and treat infectious diseases.

Investors Business Daily

How This Top Small-Cap Growth Fund Wins Big

In a stock market that favors the giants, it's still possible to reap big gains investing in Wall Street's small fries.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

ADMA Biologics Sees Composite Rating Move Up To 96

The IBD SmartSelect Composite Rating for ADMA Biologics rose from 93 to 96 Friday.

Investors Business Daily

ADMA Biologics Sees Composite Rating Climb To 96

ADMA Biologics saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.

Investors Business Daily

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle

ADMA stock rocketed Friday after the biotech company inked a deal with KPMG as its new independent registered public accounting firm.

Investors Business Daily

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns

ADMA stock plummeted Thursday after the company's auditor unexpectedly resigned. But ADMA Biologics kept its guidance for this year and next.

Investors Business Daily

The Real Best Stock Of The Year Isn't In The S&P 500 Yet

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

Investors Business Daily

Chart of the Day: ADMA Biologics - Hitting New Highs

The Chart of the Day belongs to the biomedical company ADMA Biologics (ADMA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why ADMA Biologics Shares Are Rising Today

ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center.

Benzinga

Looking Into ADMA Biologics's Return On Capital Employed

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

Benzinga

Recap: ADMA Biologics Q1 Earnings

ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.

Benzinga

Earnings Outlook For ADMA Biologics

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

Benzinga

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.

Benzinga

ADMA Biologics's Earnings Outlook

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.09.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.